Lyons, G., Thompson, J., Lousada, I., Catini, J., Manwani, R., & Maurer, M. S. (2025). Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database. Open Heart, 12(1), e003124. https://doi.org/10.1136/openhrt-2024-003124

Ramachandran, R., Shah, D., Luo, C., Shah, V., Cliff, E. R. S., Sanchorawala, V., Lentzsch, S., & Chakraborty, R. (2024). The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood Advances, 8(13), 3464–3467. https://doi.org/10.1182/bloodadvances.2024012737

Chakraborty, R., Milani, P., Palladini, G., & Gertz, M. (2023). Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies. The Lancet Haematology, 10(11), e936–e940. https://doi.org/10.1016/s2352-3026(23)00175-8

Kumar, S., Dispenzieri, A., Bhutani, D., Gertz, M., Wechalekar, A., Palladini, G., Comenzo, R., Fonseca, R., Jaccard, A., Kastritis, E., Schönland, S., la Porte, C., Pei, H., Tran, N., & Merlini, G. (2023). Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid, 30(3), 268–278. https://doi.org/10.1080/13506129.2022.2164488

Chakraborty, R., Rosenbaum, C., Kaur, G., Bhutani, D., Radhakrishnan, J., Mapara, M. Y., Maurer, M., & Lentzsch, S. (2023). First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara–VCD front‐line therapy. British Journal of Haematology, 201(5), 913–916. Portico. https://doi.org/10.1111/bjh.18733

Basdavanos, A., Maurer, M. S., Ives, L., Derwin, K., Ricchetti, E. T., Seitz, W., & Hanna, M. (2023). Prevalence of Orthopedic Manifestations in Patients With Cardiac Amyloidosis With a Focus on Shoulder Pathologies. The American Journal of Cardiology, 190, 67–74. https://doi.org/10.1016/j.amjcard.2022.11.014

Muchtar, E., Dispenzieri, A., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schönland, S., Veelken, K., Hegenbart, U., Geyer, S. M., Kumar, S. K., Kastritis, E., Dimopoulos, M. A., Liedtke, M., Witteles, R., Sanchorawala, V., Szalat, R., Landau, H., Petrlik, E., … Gertz, M. A. (2023). Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. Journal of Clinical Oncology, 41(7), 1393–1403. https://doi.org/10.1200/jco.22.00643

Landau, H. J., Orlando, E., Rodriguez, E. S., Applebaum, A., Mitchell, H.-R., Peled, J. U., Khan, N., Funnell, T., Chung, D., Scordo, M., Shah, G. L., LeStrange, N. J., Hambright, K. A., McElrath, C. M., Cazeau, N., Devlin, S. M., Perales, M.-A., van den Brink, M. R. M., & Giralt, S. A. (2022). Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 28(12), 832.e1-832.e7. https://doi.org/10.1016/j.jtct.2022.09.014

Javaugue, V., Rocha, A. B., Said, S. M., Santoriello, D., Hou, J., Dasari, S., Theis, J. D., Vrana, J. A., Batal, I., Larsen, C., Markowitz, G. S., D’Agati, V. D., McPhail, E. D., Leung, N., & Nasr, S. H. (2022). Clinicopathologic and proteomic characteristics of intratubular cytoplasmic AL amyloidosis. Kidney International, 102(4), 926–929. https://doi.org/10.1016/j.kint.2022.07.020

Hopson, M. B., Bhutani, D., Sarkaria, S., Maurer, M. S., Griffin, J. M., Mapara, M., Lentzsch, S., & Chakraborty, R. (2022). Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis. Leukemia & Lymphoma, 63(9), 2109–2113. https://doi.org/10.1080/10428194.2022.2060502

Maurer, M. S., Dunnmon, P., Fontana, M., Quarta, C. C., Prasad, K., Witteles, R. M., Rapezzi, C., Signorovitch, J., Lousada, I., & Merlini, G. (2022). Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 15(6). https://doi.org/10.1161/circheartfailure.121.009038

Cuddy, S. A. M., Jerosch-Herold, M., Falk, R. H., Kijewski, M. F., Singh, V., Ruberg, F. L., Sanchorawala, V., Landau, H., Maurer, M. S., Yee, A. J., Bianchi, G., Di Carli, M. F., Liao, R., Kwong, R. Y., & Dorbala, S. (2022). Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 15(4), 594–603. https://doi.org/10.1016/j.jcmg.2021.09.032

Edwards, C. V., Rao, N., Bhutani, D., Mapara, M., Radhakrishnan, J., Shames, S., Maurer, M. S., Leng, S., Solomon, A., Lentzsch, S., & Eisenberger, A. (2021). Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood, 138(25), 2632–2641. https://doi.org/10.1182/blood.2020009039